Compositions and methods for treating hoof diseases

Abstract

The present invention is generally directed to compositions and methods for the treatment of an infectious disease of the foot of an animal. One aspect of the invention is directed to a method for preventing and/or treating one or more infectious diseases of the hoof in animals, comprising: preparing a copper-free and zinc-free composition comprising at least one cross-linking agent, wherein the cross-linking agent is not formaldehyde; and administering the composition to a lower leg and hoof area of said animal to prevent and/or treat said one or more infectious diseases. Another aspect of the invention is directed to a copper-free and zinc-free composition for the treatment and/or prevention of one or more infectious diseases of the hoof in animals, comprising at least one cross-linking agent, wherein said cross-linking agent is not formaldehyde. The present invention is also directed to a method for treating and/or preventing papillomatous digital dermatitis in an ungulate, comprising: preparing a copper-free and zinc-free composition comprising at least one cross-linking agent and at least one quaternary ammonium compound; and spraying or applying in a foam a therapeutically effective amount of said composition to a lower leg and hoof area of said ungulate in order to treat and/or prevent said papillomatous digitial dermatitis.

1 - 20 . (canceled) 
     
     
         21 . A composition comprising glutaraldehyde and glyoxal, wherein said composition is substantially free of formaldehyde, copper and zinc. 
     
     
         22 . The composition of  claim 21 , wherein said composition is used for the treatment and/or prevention of one or more infectious diseases of the hoof in animals. 
     
     
         23 . The composition of  claim 22 , wherein said infectious disease of the foot is hairy heel warts, foot rot, stable foot rot, or foot scald. 
     
     
         24 . The composition of  claim 21 , further comprising at least one other cross-linking agent. 
     
     
         25 . The composition of  claim 24 , wherein said cross-linking agent is selected from the group consisting of ortho-phthaldehyde, carbodiimides, diisocyanates, a formaldehyde donor, sodium hydroxymethyl glycinate, diazolidinyl urea, imidazolidinyl urea, dimethylol-5,5-dimethylhydantoin, dimethylol urea, 2-bromo-2-nitropropane 1,3-diol, quatemium-15, parabens, 5-chloro-2methylisothiazolin-3-one, 1,2-dibromo-2,4-dicyanobutane, ethanol, other alcohols, and polyol. 
     
     
         26 . The composition of  claim 24 , wherein said cross-linking agent is selected from the group consisting of glyceraldehyde, dextran dialdehyde, ethylene glycol, di(ethylene glycol), polyethylene glycol, propylene glycol, di(propylene) glycol, polypropylene glycol, ethylene glycol dimethacrylate, di(ethylene glycol) dimethacrylate, poly(ethylene glycol) dimethacrylate, poly(lauryl methacrylate-co-ethylene glycol dimethacrylate), propylene glycol dimethacrylate, di(propylene glycol) dimethacrylate, polypropylene glycol) dimethacrylate, malonic dihydrazide, ethylmalonic dihydrazide, succinic dihydrazide, glutaric dihydrazide, adipic dihydrazide, isophthalic dihydrazide, oxalyl dihydrazide, pimelic dihydrazide, 3,3′-sulfonyldibenzenesulfonic dihydrazide, m-xylylene isocyanate, 4-methyl-m-phenylene diisocyanate, 2-methyl-m-phenylene diisocyanate, 3,3′-dimethoxy-4,4′-biphenylene diisocyanate, 4-Br-6-methyl-1,3-phenylene diisocyanate, 4-Cl-6-methyl-1,3-phenylene diisocyanate, toluene 2,4-diisocyanate, 1,3-phenylene diisocyanate, 1,4-phenylene diisocyanate, 2,4,6-trimethyl-1,3-phenylene diisocyanate, 1,4-diisocyanatebutane, 1,6-diisocyanatehexane, 1,8-diisocyanateoctane, isophorone diisocyanate, N,N-(3-dimethylaminopropyl)-N-ethyl carbodiimide (EDC), calcium chloride, divinylsulfone, sulfonylurea, hydrolysable polyrotaxane, L-lysine methyl ester, and genipin. 
     
     
         27 . The composition of  claim 21 , wherein the composition further comprises at least one antimicrobial essential oil or at least one active ingredient thereof or a mixture thereof. 
     
     
         28 . The composition of  claim 21 , wherein the composition further comprises at least one poly(alkylene glycol) alkyl ether. 
     
     
         29 . The composition of  claim 21 , wherein the composition further comprises at least one gelling agent. 
     
     
         30 . The composition of  claim 21 , wherein the composition further comprises at least one quaternary ammonium compound. 
     
     
         31 . The composition of  claim 21 , wherein the composition further comprises at least one surfactant. 
     
     
         32 . The composition of  claim 21 , wherein the composition further comprises one or more ethoxylated nonlyphenols. 
     
     
         33 . The composition of  claim 21 , wherein said composition comprises about 5% to about 30% by weight of glutaraldehyde and about 5% to about 30% by weight of glyoxal. 
     
     
         34 . A composition for the treatment of one or more infectious diseases of the hoof in animals, comprising one or more cross-linking agents, excluding formaldehyde; and one or more quaternary ammonium compounds. 
     
     
         35 . The composition of  claim 34 , wherein said cross-linking agent is selected from the group consisting of glutaraldehyde and glyoxal. 
     
     
         36 . The composition of  claim 34 , wherein said cross-linking agent is selected from the group consisting of glutaraldehyde, glyoxal, glyceraldehyde, dextran dialdehyde, ethylene glycol, di(ethylene glycol), polyethylene glycol, and propylene glycol. 
     
     
         37 . A method for treating and/or preventing papilomatous digital dermatitis in an ungulate, comprising preparing a substantially copper-free and zinc-free composition comprising at least one aldehyde and at least one quaternary ammonium compound; and administering a therapeutically effective amount of said composition to a lower leg and hoof area of said ungulate. 
     
     
         38 . The method of  claim 37 , wherein the administering step comprises a foam that contains the active ingredients, a spray that contains the active ingredients, or a foot bath that contains the active ingredients.